Upon CLL disease onset (>5% CD45+/CD19+/CD5+ PBLs), mice were randomly assigned to receive OPN5 or vehicle equivalent (VEH) treatment daily for three weeks (Figure 3A). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.